Vor Biopharma Earnings Estimate

VOR Stock  USD 2.05  0.16  7.24%   
By analyzing Vor Biopharma's earnings estimates, investors can diagnose different trends across Vor Biopharma's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Vor Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Vor Biopharma is projected to generate -0.171875 in earnings per share on the 31st of December 2025. Vor Biopharma earnings estimates show analyst consensus about projected Vor Biopharma EPS (Earning Per Share). It derives the highest and the lowest estimates based on Vor Biopharma's historical volatility. Many public companies, such as Vor Biopharma, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Vor Biopharma's earnings estimates, investors can diagnose different trends across Vor Biopharma's analyst sentiment over time as well as compare current estimates against different timeframes. As of 07/22/2025, Gross Profit is likely to drop to about (3.3 M)Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Vor Biopharma Earnings per Share Projection vs Actual

About Vor Biopharma Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Vor Biopharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Vor Biopharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Vor Biopharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-457 M-434.1 M
Retained Earnings Total Equity-200 M-210 M
Earnings Yield(1.53)(1.46)
Price Earnings Ratio(0.65)(0.68)
Price Earnings To Growth Ratio 0.23  0.37 

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vor Stock

  0.61JNJ Johnson JohnsonPairCorr
  0.61MRK Merck Company Earnings Call This WeekPairCorr
  0.62PFE Pfizer IncPairCorr

Moving against Vor Stock

  0.57BCH Banco De Chile Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.